NCT03251092: An overdue trial by Proteostasis Therapeutics, Inc.
This trial is overdue. It was due to report 4 years, 8 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT03251092 |
|---|---|
| Title | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults With Cystic Fibrosis |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 17, 2017 |
| Completion date | Dec. 23, 2019 |
| Required reporting date | Dec. 22, 2020, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | 1693 |